Patents
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
09/2002
09/11/2002EP1165122B1 Use of molecular weight-amplified hirudin as an anticoagulant in extracorporeal renal replacement therapy
09/11/2002EP1100463B1 New injectable formulations containing ramoplanin
09/11/2002EP1073444A4 A food composition and method of using same
09/11/2002EP1054892B1 Azole peptidomimetics as thrombin receptor antagonists
09/11/2002EP1003539A4 FLUORESCENT AMYLOID A beta PEPTIDES AND USES THEREOF
09/11/2002EP0989854A4 Compositions useful as fibrin sealants
09/11/2002EP0954527A4 Glycine transporter-transfected cells and uses thereof
09/11/2002EP0910399B1 Stable pharmaceutical composition of bdnf
09/11/2002EP0871467B1 Formulation for peptide release
09/11/2002EP0853484B1 Novel mu opioid receptor ligands: agonists and antagonists
09/11/2002EP0832098B1 Method of producing igf-i and igfbp-3 with correct folding and disulfide bonding
09/11/2002EP0813529B1 Arginine analogues having nitric oxide synthase inhibitor activity
09/11/2002EP0808169A4 Programmed cell death genes and proteins
09/11/2002EP0769942B1 Use of a cationic amphipathic compound as a transfection agent, vaccine additive or drug
09/11/2002EP0762870B1 Virosome-mediated intracellular delivery of therapeutic agents
09/11/2002EP0759776B1 Use of igf-i or analogues thereof in the prevention of diabetes
09/11/2002EP0603399B1 Endothelin-antagonizing peptide
09/11/2002CN1369015A Recombinant anti-CD 40 antibody and uses thereof
09/11/2002CN1369009A Modified chimeric polyeptides with improved pharmacokinetic properties
09/11/2002CN1368978A Novel proteins and uses thereof
09/11/2002CN1368899A Preparation of therapeutic composition
09/11/2002CN1368892A Sustained release formulation of peptide
09/11/2002CN1368887A Mycophenolate Mofetil in association with PEG-IFN alpha
09/11/2002CN1368885A Compositions and methods for identifying antigens which elicit an immune response
09/11/2002CN1368879A Use of (-)(3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance type 2 diabetes, hyperlipidemia and hyperuricemia
09/11/2002CN1368877A Amphiphilic drug-oligomer conjugates with hydrolyzable lipophile components and methods for making and using the same
09/11/2002CN1368875A Supercritical fluid-assisted nebulization and bubble drying
09/11/2002CN1368874A Implantable active ingredient depot
09/11/2002CN1368511A Human protein with cancer inhibiting function and its coding sequence
09/11/2002CN1368510A Human protein with suppression to cancer cell growth and its coding sequence
09/11/2002CN1368509A Human protein with suppression to cancer cell growth and its coding sequence
09/11/2002CN1368508A Human protein with cancer inhibiting function and its coding sequence
09/11/2002CN1368383A Precision and preparing process of health-care compound hormone product
09/11/2002CN1368382A Usage of hypophloeodal colyone and its application
09/11/2002CN1368381A Liquid T cell factor preparation
09/11/2002CN1090676C Expression systems utilizing autolyzing fusion proteins and novel reducing polypeptide
09/11/2002CN1090508C Storage stable water solution for infusion containing thrombin inhibitor
09/11/2002CN1090507C Novel pharmaceutical application of nonimmunogenproteinic material and composition
09/11/2002CN1090506C Application of lysozyme dimer
09/11/2002CN1090505C 多功能酶 Multifunctional enzyme
09/10/2002US6448468 Transgenetic mouse which comprises an inactive Peg3 gene, and the use thereof
09/10/2002US6448382 Loading a mixture of isoforms onto a tsk sulfopropyl cation exchange chromatography column, washing with linear gradient buffer, discarding fraction comprising double clipped isoform and collecting intact and single-clipped isoforms
09/10/2002US6448380 Complexing
09/10/2002US6448379 Inhibitors to il8 receptor binding, including antibodies, that interact with the amino-terminal extracellular domain of the il8 receptor and compete with il8 and other related natural ligands, for receptor-binding.
09/10/2002US6448378 Made by preparing a purified solution of monoreactive-amine modified collagen, such as glutaric anhydride derivatized collagen, heating to reduce viscosity and adding the drug to the solution, casting into thin layers, drying into film
09/10/2002US6448376 Two new proteins which appear to be new members of the e2f gene family, called e2f-5
09/10/2002US6448375 Active and inactive CC-chemokine receptor
09/10/2002US6448374 Production of phosphopeptides from casein
09/10/2002US6448292 Comprising a diglyceride in which at least 55% by weight of constitutive acyl groups are unsaturated acyl groups and 15 to 100% by weight thereof are omega 3 type unsaturated acyl groups having at least 20 carbon atoms and a triglyceride
09/10/2002US6448278 Antiscarring agent
09/10/2002US6448263 Synthesis routes for such as 2-amino-n-(2-(3a-(r)-benzyl-2-methyl-3-oxo-2,3,3a,4,6,7-hexahydro-pyrazolo -(4,3-c) pyridin-5-yl)-1-(r)-benzyloxymethyl-2-oxo-ethyl)-isobutyramide l-tartaric acid salt
09/10/2002US6448234 Compounds and methods for treatment and diagnosis of chlamydial infection
09/10/2002US6448231 Presynaptic neurotoxin such as botulinum toxin a
09/10/2002US6448230 Testis expressed polypeptide
09/10/2002US6448229 Gamma secretase inhibitors
09/10/2002US6448227 Therapeutically effective substance mixture
09/10/2002US6448225 Human growth hormone aqueous formulation
09/10/2002US6448224 Antibiotics and methods of using the same
09/10/2002US6448223 Antagonists of HMG1 for treating inflammatory conditions
09/10/2002US6448222 Antitumor agent; antimetastasis agent
09/10/2002US6448221 By administering an adipocyte complement related protein to reduce platelet aggregation
09/10/2002US6448093 Solubilization of hyaluronic acid in aqueous solution of electrolyte and acid; solubilization of polar substancec (i.e. a plasmid) in mixture; acidification; dialyzing said mixture to reduce an ionic concentration past point of collapse
09/10/2002US6448081 Oligonucleotides specifically hybridizable with nucleic acids encoding interleukin 12 p40 subunit
09/10/2002US6448080 Antisense modulation of WRN expression
09/10/2002US6448079 Inhibiting the expression of p38 mitogen activated protein kinase in cells or tissues comprising contacting said cells or tissues in vitro with the antisense compound
09/10/2002US6448078 Inhibiting human vpr interacting protein activity in a cell using a nucletide sequence complementary to a portion of the nucleotide sequence that encodes hvip; anticancer agent
09/10/2002US6448077 Chimeric and humanized monoclonal antibodies specific to VEGF receptors
09/10/2002US6448072 Human transcription factor iia (tfiia) is a cellular factor that, together with additional protein components, regulates the expression of human genes
09/10/2002US6448071 Effective competitors to t cell receptors and mhc molecules normally involved in transplant rejection and autoimmune disease
09/10/2002US6448059 Methods and composition for inhibition of tRNA activities
09/10/2002US6448054 Locally administering to a specific site a fugetactic agent in an amount effective to repel immune cells
09/10/2002US6448044 DNA encoding human natural killer cell activating factor II
09/10/2002US6448042 These enzymes have been implicated in a variety of disease processes, including tumor cell invasion, tumor angiogenesis and rheumatoid arthritis
09/10/2002US6448041 Colon cancer marker
09/10/2002US6448040 Nucleic acid molecules encoding hypusine mutants having the biological activity, of inhibiting cellular proliferation
09/10/2002US6448038 BirA from staphylococcus aureus
09/10/2002US6448037 PgsA
09/10/2002US6448036 ribB
09/10/2002US6448035 Disorders mediated by disease states associated with suppressed immune function can be treated by administering a soluble form of the negative signaling lir
09/10/2002US6448032 With anti-inflammatory and antipyretic function and involved in a number of diseases such as melanoma and skin cancer
09/10/2002US6448022 Method for evaluating inhibition of human chorionic gonadotropin (hcg) production of a subject's trophoblast cells comprising the steps of isolating a regulatory polypeptide inhibits, in a dose dependent manner, the production of hcg by
09/10/2002US6448020 Molecules associated with the human suppressor of fused gene
09/10/2002US6448011 Isolated nucleic acid, vectors, transformed mammalian cells and non-human transgenic animals that encode and express normal or mutant adrenergic receptor genes.
09/10/2002US6448009 Method for target site selection and discovery
09/10/2002US6448006 Methods and compositions for reducing bacterial tolerance to antibacterials disinfectants and organic solvents
09/10/2002US6448000 Viral growth and cellular genes that function as tumor suppressors. thus, the present invention provides nucleic acids related to and methods of reducing or preventing viral infection or cancer. the invention also provides methods of
09/10/2002US6447996 Polypeptides having galanin receptor activity, genetic material for expressing same, any recombinant cell expressing said polypeptides, and the use thereof, are disclosed.
09/10/2002US6447808 Pharmaceutical or veterinary composition for treating wounds comprising milk product extracts including growth factors with basic to neutral isoelectric points
09/10/2002US6447806 Water insoluble cyclosporin colloids having charged phosphatides on the surface as stabilizers; drug delivery
09/10/2002US6447796 Sustained release hydrophobic bioactive PLGA microspheres
09/10/2002US6447787 Methods for enhancing wound healing
09/10/2002US6447786 Cyclic oligopeptides used as controllers of rna transcription factors in staphylococcus grampositive bacteria; prevention of infections
09/10/2002US6447785 Method for treating hypercalcemia
09/10/2002US6447784 Genetically engineered salmonella for use in the treatment of cancer
09/10/2002US6447783 Compositions comprising FGF9 and use thereof for stimulating cartilage and bone repair
09/10/2002US6447781 Administering protein complexes including antigens to humans for prevention of adenocarcinomas, melanomas, neuroblastomas, leukemia, lymphomas and mylomas; immunology; vaccines
09/10/2002US6447780 Administering heat shock proteins (hsp) complexed with antigens; antigrowth agents or development inhibitors for cancer; immunology; vaccines
09/10/2002US6447777 Polymerized staphylococcal protein a for treatment of diseases
09/10/2002US6447776 Monoclonal antibodies against mutant amino acid sequences generated by genetic deletions or point mutations; detection of cancer
09/10/2002US6447775 Prevention of endocytosis and metabolism of amyloid precursor proteins by blocking the binding to low density lipoprotein receptors (lrp); antigens